Related Experiment Video

Updated: Feb 7, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.2K

Olaratumab in the management of advanced soft tissue sarcoma

Chrystia M Zobniw1, Van Anh Trinh1, Kristi Posey2

  • 11 Division of Pharmacy, Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|July 24, 2018
PubMed

Insights

Olaratumab, an anti-PDGFRα antibody, combined with doxorubicin shows promise for advanced soft tissue sarcoma. This combination has a tolerable safety profile, with ongoing trials to confirm its role in treatment.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Advanced soft tissue sarcoma (STS) presents a significant clinical challenge.
  • Current treatment options for advanced STS have limitations in efficacy and survival benefits.
  • Targeted therapies are being investigated to improve outcomes for STS patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of olaratumab in combination with doxorubicin for advanced soft tissue sarcoma.
  • To assess the impact of this combination on progression-free survival (PFS) and overall survival (OS).
  • To characterize the safety profile of the olaratumab-doxorubicin regimen.

Main Methods:

  • A contingent approval was granted for olaratumab in combination with doxorubicin.
  • An ongoing confirmatory Phase 3 trial is evaluating survival data.
  • Safety profile was assessed, comparing it to doxorubicin monotherapy.

Main Results:

  • The olaratumab-doxorubicin combination demonstrated potential for improving PFS and OS in advanced STS.
  • The safety profile was generally tolerable, similar to doxorubicin monotherapy.
  • Infusion-related reactions were noted as an exception in the safety profile.

Conclusions:

  • Olaratumab in combination with doxorubicin offers a new therapeutic option for advanced soft tissue sarcoma.
  • Further data from the ongoing Phase 3 trial are crucial to establish its definitive role in treatment algorithms.
  • Future research will focus on predictive biomarkers, pediatric applications, and combination therapies.
Keywords:
IMC-3G3Soft tissue sarcomaanti-PDGFRα monoclonal antibodyolaratumabsarcoma

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.3K
Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

979

Related Concept Videos

Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques01:30

Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques

Airway management is essential in emergency and surgical medicine, ensuring ventilation and oxygenation in patients who cannot maintain their own airway. Clinicians use a range of techniques and devices to secure the airway, depending on the patient’s condition and the clinical context. Key methods include endotracheal intubation, rapid sequence intubation (RSI), supraglottic airway devices, and advanced visualization aids. In cases where these approaches fail, surgical airway...
561
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.4K
Overview of Advanced Functional Groups02:22

Overview of Advanced Functional Groups


Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
30.1K
Extraction: Advanced Methods00:56

Extraction: Advanced Methods

Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
1.2K
Tonsillitis II: Management01:26

Tonsillitis II: Management

This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
439
Impression Management Techniques I: Managing Appearances01:29

Impression Management Techniques I: Managing Appearances

Appearance is a multidimensional aspect of self-presentation that encompasses observable attributes such as clothing, grooming, speech, and nonverbal behavior. These elements are often strategically managed to align with socially constructed expectations in different settings. For instance, individuals tailor their appearance during job interviews, social gatherings, or athletic events to meet the perceived norms of those environments.Contextual Adaptation and Social SignalsThe research...
220